Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Qian Shi, Alberto F. Sobrero, Anthony Frank Shields, Takayuki Yoshino, James Paul, Julien Taieb, Ioannis Sougklakos, Rachel Kerr, Roberto Labianca, Jeffrey A. Meyerhardt, Franck Bonnetain, Toshiaki Watanabe, Ioannis Boukovinas, Lindsay A. Renfro, Axel Grothey, Donna Niedzwiecki, Valter Torri, Thierry Andre, Daniel J. Sargent, Timothy Iveson
Institutions: Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), Ospedale Policlinico San Martino, Wayne State University, The Barbara Ann Karmanos Cancer Institute, National Cancer Center Hospital, University of Glasgow, Hôpital Européen Georges-Pompidou, University of Oxford, Ospedale Papa Giovanni XXIII, Dana-Farber Cancer Institute, Inserm, Methodology and Quality of Life Unit in Oncology, Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, The University of Tokyo, Duke University, Mario Negri Institute for Pharmacological Research, Hôpital Saint-Antoine, University Hospital Southampton NHS Foundation Trust
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4231163380